In a study presented at MDS 2021, researchers assessed the progression of spinocerebellar ataxias type 1, 2, 3, and 6, an autosomal dominantly inheritance, to identify factors that influence the transition to higher disability.
In a study presented at MDS 2021, researchers assessed whether patients with tic disorders with or without major psychoses were at risk of developing tardive dyskinesia.
At MDS 2021, researchers shared study results on the effect of Parkinson disease (PD)-related genes on the risk for cardiovascular events among patients with genetic forms of PD, including those with variations in the LRRK2 and GBA genes.
At MDS 2021, researchers shared results of a genetics investigative analysis on variations in the BSN gene in patients with multiple system atrophy.
In a systematic review and network meta-analysis presented at MDS 2021, researchers assessed the effect of device-aided strategies on off-time improvement and quality of life in Parkinson disease.
Researchers observed the differences in the effect of COVID-19 stressors on mental health and quality of life in subgroups of patients with Parkinson disease.
Researchers assessed the features of Parkinson disease (PD) pathophysiology that may increase the risk for COVID-19 mortality among hospitalized patients with PD.
Researchers analyzed brain MRI characteristics of patients with Huntington disease and related them to the major manifesting symptoms at clinical onset.
Researchers shared their findings on the cerebrospinal fluid profile of patients with fragile X-associated tremor/ataxia syndrome and potential biomarkers.
In a poster presented at MDS 2021 and as part 2 of the MOVES-PD trial, researchers assessed the safety and efficacy of venglustat, a glucosylceramide synthase inhibitor, in patients stratified by GBA gene variation severity.